GlassScriptPhysician profile
Carmen E Morales
NPI 1740290246
$4,200.31
in general payments reported to CMS, 2019-2025
30 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.83 · 2021: $343 · 2022: $306 · 2023: $1,443 · 2024: $760 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.51 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $874.31 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $796.97 | 2021-2025 | |
| Novo Nordisk INC | $423.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $302.74 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $293.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $197.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $179.04 | 2023-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $141.91 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $139.57 | 2023-2024 | Myrbetriq, Veozah |
| Biosense Webster, INC. | $138.05 | 2022 | |
| Pfizer INC. | $125.21 | 2021-2025 | |
| Amgen INC. | $78.39 | 2020-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $61.86 | 2024 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $44.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $43.64 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $42.03 | 2023-2024 | Auvelity |
| Lundbeck LLC | $37.77 | 2024 | Rexulti |
| Boston Scientific Corporation | $34.16 | 2023 | |
| Sanofi-Aventis U.S. LLC | $25.77 | 2025 | |
| Corcept Therapeutics | $23.66 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.44 | 2025 | Jardiance |
| Hologic Sales and Service, LLC | $23.32 | 2023 | Coolseal Generator |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.11 | 2023 | Xifaxan |
| Amarin Pharma, INC. | $22.86 | 2020 | |
| Merck Sharp & Dohme LLC | $20.54 | 2020 | |
| Ucb, INC. | $20.45 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.59 | 2022 | |
| Philips North America LLC | $16.36 | 2023 | |
| Sanofi Pasteur INC. | $15.45 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.